Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like AbbVie Plans to Hire After Doubling Cambridge R&D Facility February 1, 2018 Novartis AG's Phase III Drug for Heart Failure Bombs Trial March 21, 2017 Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug July 4, 2017